After a year of historic profits in 2021 following the mass roll-out of COVID-19 vaccines and related treatments, big pharma companies armed with cash for deals have been shifting their attention -
Overall, pharma, medical...more
2/3/2023
/ Acquisitions ,
Biotechnology ,
Coronavirus/COVID-19 ,
Global Dealmaking ,
Healthcare ,
Investment ,
Investors ,
Life Sciences ,
Mergers ,
Pharmaceutical Industry ,
Prescription Drugs ,
Vaccinations
Although the record-breaking deal activity of 2021 spilled over into 2022, headwinds in the first quarter developed into a significant slowdown during the rest of 2022, with an expectation of continued slowness as we enter...more
1/30/2023
/ Acquisitions ,
Buyers ,
Capital Markets ,
CFIUS ,
Coronavirus/COVID-19 ,
Cryptocurrency ,
Department of Justice (DOJ) ,
Domestic Dealmaking ,
Environmental Social & Governance (ESG) ,
EU ,
Federal Trade Commission (FTC) ,
Financial Institutions ,
Financial Services Industry ,
Global Dealmaking ,
Investment ,
Investors ,
Mergers ,
Pharmaceutical Industry ,
Private Equity ,
Publicly-Traded Companies ,
Real Estate Market ,
Securities and Exchange Commission (SEC) ,
Sellers ,
Special Purpose Acquisition Companies (SPACs) ,
Technology
Technology M&A activity is thriving in 2021 as dealmakers continue to turn to the sector in search of assets with high-quality earnings and growth prospects -
Technology deal volume and value surged through the first half...more
7/30/2021
/ Acquisitions ,
Antitrust Division ,
Biden Administration ,
Digital Health ,
Domestic Dealmaking ,
Global Dealmaking ,
Healthcare ,
Mergers ,
Private Equity ,
Publicly-Traded Companies ,
Special Purpose Acquisition Companies (SPACs) ,
Technology Sector
Soaring demand in high-growth industries is causing a steady flow of PE investment into the sector -
While 2020 was a tumultuous year for global dealmaking, private equity (PE) activity within the consumer sector finished...more